Clinical trials: Gefitinib, completed
Cancer
Open-Label Extension of Other SZ1839 (Iressa) Trials
A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.
- Trial name
- NCT00635973
- Testing
- Gefitinib (Iressa)
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Phase II Iressa & Carbo/Gem in NSCLC
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
- Trial name
- NCT00264498
- Testing
- Gefitinib, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth…
- Trial name
- NCT00026299
- Testing
- ZD1839, oxaliplatin
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Chicago
Lung Cancer
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898924
- Testing
- molecular diagnostic method, mutation analysis
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Gefitinib in Treating Patients With Malignant Mesothelioma
Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant…
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00025207
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
- Trial name
- NCT02179671
- Testing
- Gefitinib, AZD9291, Selumetinib+Docetaxel
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
This is an open-label phase 1, safety, PK, and preliminary efficacy study of oral Gefitinib and IV Tremelimumab in previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have…
- Trial name
- GEFTREM (NCT02040064)
- Testing
- Gefitinib, Tremelimumab
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
IRESSA™ (Gefitinib) in Breast Cancer Patients
This is a phase II trial to assess whether IRESSA™ (gefitinib) has anti-tumour efficacy in patients with breast cancer. The trial proposes to enter 27 patients who have acquired resistance to tamoxifen and 27 patients with ER…
- Trial name
- NCT00632723
- Testing
- gefitinib (IRESSA™, ZD1839)
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Lung Cancer
A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer
A randomized phase III trial of platinum-based chemotherapy alone versus platinum-based chemotherapy followed by maintenance therapy with gefitinib in patients with stage IIIB/IV NSCLC.
- Trial name
- NCT00144066
- Testing
- platinum-based chemotherapy alone (up to six cycles), platinum-based chemotherapy followed by maintenance therapy with gefitinib
- Volunteers
- 600 people
- Sponsor
- West Japan Thoracic Oncology Group
Cancer
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
This is a phase II, open-label trial of Gefitinib and docetaxel in patients having one prior regimen of chemotherapy for with metastatic pancreatic carcinoma.
- Trial name
- NCT00177242
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Pittsburgh
Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?
Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?
Not significantly increased survival in T/T
- Trial name
- NCT02740894
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Lung Cancer
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor.
- Trial name
- NCT00062062
- Testing
- carboplatin, gefitinib, paclitaxel
- Where
- 141 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small-cell Lung Cancer
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer
- Trial name
- NCT00255489
- Testing
- Gefitinib, palliative thoracic radiotherapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Recurrent Glioblastoma
Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).
- Trial name
- NCT00250887
- Testing
- Gefitnib
- Where
- Switzerland
- Volunteers
- 22 people
- Sponsor
- University of Zurich
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the…
- Trial name
- NCT00041106
- Testing
- gemcitabine hydrochloride, cisplatin, gefitinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
This is a study of gefitinib plus olaparib gefitinib in combination with olaparib (AZD2281) versus gefitinib alone, in patients with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced non-small-cell lung cancer.
- Trial name
- GOAL (NCT01513174)
- Testing
- Gefitinib, Olaparib
- Where
- 5 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Spanish Lung Cancer Group
Non-small Cell Lung Cancer
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation lung cancer.
- Trial name
- PROGRESS (NCT02804776)
- Testing
- Gefitinib
- Where
- Singapore
- Volunteers
- 15 people
- Sponsor
- National Cancer Centre, Singapore
Head and Neck Cancer, Carcinoma, Squamous Cell
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
To determine safety profile of the epidermal growth factor receptor (EGFR) antagonist, ZD1839 in combination with cisplatin and radiation therapy in patients with local-regional recurrent squamous cell cancer of the head and…
- Trial name
- NCT00185835
- Testing
- ZD-1839, Cisplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University